{"filings":[{"id":49561,"accession_number":"0001104659-26-059700","cik":1953926,"company_name":"Zenas BioPharma, Inc.","ticker":"ZBIO","form_type":"8-K","filed_at":"2026-05-13T10:14:34+00:00","items":["2.02","5.02","5.07","9.01"],"status":"ready","headline":"Zenas BioPharma Q1 net loss $81M; obexelimab BLA on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $81.0M in Q1 2026 vs $33.6M in Q1 2025; R&D expenses rose to $60.4M.","Cash and investments $718.5M as of Mar 31; raised $419M year-to-date from offerings and debt facility.","Obexelimab BLA for IgG4-RD expected this quarter; EMA filing H2 2026; INDIGO data at EULAR June 4.","Phase 2 SunStone SLE trial enrollment completed; topline results expected Q4 2026.","Director Tomas Kiselak did not stand for re-election; board size reduced by one."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1126300000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111247,"accession_number":"0001104659-26-037821","cik":1953926,"company_name":"Zenas BioPharma, Inc.","ticker":"ZBIO","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Zenas BioPharma raises ~$287M via convertible notes and equity to fund pipeline and launch","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Closed $200M aggregate principal of 2.50% Convertible Senior Notes due 2032; net proceeds ~$193.7M.","Closed public equity offering of 5M shares at $20.00/share; net proceeds ~$93.7M.","Combined net proceeds ~$287.4M; funds obexelimab launch (if approved), orelabrutinib Phase 3, ZB021 Phase 1/2, and working capital.","Underwriters granted 30-day options: up to $30M additional notes and 750k additional shares.","Company previously had going concern doubt; capital raise aims to address liquidity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1126300000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111246,"accession_number":"0001104659-26-027961","cik":1953926,"company_name":"Zenas BioPharma, Inc.","ticker":"ZBIO","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zenas BioPharma Q4/FY2025 net loss $377.7M; obexelimab BLA filing on track Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2025 net loss of $377.7M vs $157.0M in FY2024; Q4 net loss $240.4M.","Cash and investments $360.5M at Dec 31, 2025; expects funding into Q2 2027.","Up to $250M debt facility from Pharmakon; $75M drawn at closing.","Obexelimab BLA for IgG4-RD to FDA in Q2 2026; EMA MAA in H2 2026.","Topline Phase 2 SunStone (SLE) results expected Q4 2026; orelabrutinib Phase 3 PPMS trial initiated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1126300000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111245,"accession_number":"0001104659-26-015314","cik":1953926,"company_name":"Zenas BioPharma, Inc.","ticker":"ZBIO","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Zenas BioPharma adopts amended Short-Term Incentive Plan for annual cash bonuses","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Plan effective Jan 1, 2026; provides discretionary annual cash bonuses based on company and individual performance.","Target awards expressed as percentage of base salary; payouts capped at 150% of target.","Employees hired after Sep 30 generally ineligible; must be employed through payment date.","Administered by Board for executives and by CEO/leadership for other employees.","Company retains right to amend or discontinue plan at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1126300000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111244,"accession_number":"0001104659-26-000402","cik":1953926,"company_name":"Zenas BioPharma, Inc.","ticker":"ZBIO","form_type":"8-K","filed_at":"2026-01-05T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Zenas BioPharma reports positive Phase 3 INDIGO trial of obexelimab in IgG4-RD; plans BLA in Q2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Obexelimab met primary endpoint: 56% reduction in IgG4-RD flare risk vs placebo (HR 0.443, p=0.0005).","All four key secondary endpoints met with high statistical significance (p≤0.0049).","Safety profile favorable: SAEs 10% obexelimab vs 19% placebo; fewer infections.","Preliminary cash $360.5M as of Dec 31, 2025; expected to fund operations through end of 2026.","BLA submission to FDA planned Q2 2026; MAA to EMA H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1126300000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127858,"accession_number":"0001104659-25-121182","cik":1953926,"company_name":"Zenas BioPharma, Inc.","ticker":"ZBIO","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Zenas BioPharma adopts 2026 Inducement Plan for up to 1M shares for new hires","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Plan reserves 1,000,000 shares of common stock for equity awards to new employees as hiring inducements.","Approved Dec 10, 2025 by Board; requires Compensation Committee or independent director approval per Nasdaq Rule 5635(c)(4).","Plan exempt from stockholder approval; grants include non-statutory stock options, SARs, RSUs, and restricted stock.","Eligible individuals are new hires or rehires after a bona fide break in employment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1126300000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127857,"accession_number":"0001104659-25-109737","cik":1953926,"company_name":"Zenas BioPharma, Inc.","ticker":"ZBIO","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zenas BioPharma Q3 net loss $51.5M; obexelimab Phase 3 data expected year-end 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $51.5M (Q3 2025) vs $38.6M (Q3 2024); R&D $34.4M, G&A $13.2M.","Cash $301.6M at Sep 30; +$120M Oct private placement; runway into Q4 2026.","Obexelimab Phase 3 INDIGO topline data in IgG4-RD expected year-end 2025.","Phase 2 MoonStone RMS: 95% reduction in GdE lesions (p=0.0009); 24-week data Q1 2026.","Licensed orelabrutinib & two candidates from InnoCare; $300M Royalty Pharma deal ($75M upfront)."],"consensus_eps_estimate":-1.0686,"consensus_eps_actual":-3.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":10000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1126300000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127856,"accession_number":"0001104659-25-102317","cik":1953926,"company_name":"Zenas BioPharma, Inc.","ticker":"ZBIO","form_type":"8-K","filed_at":"2025-10-27T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Zenas BioPharma announces Phase 2 MoonStone trial of obexelimab meets primary endpoint with 95% lesion reduction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Obexelimab showed 95% relative reduction in new GdE T1 lesions vs placebo (p=0.0009) at weeks 8 and 12.","Adjusted mean new GdE T1 lesions per scan: 0.01 (obexelimab) vs 0.23 (placebo).","Safety consistent with prior trials; most common were mild injection site reactions.","Expects 24-week MoonStone data in Q1 2026; Phase 3 INDIGO (IgG4-RD) topline around year-end 2025.","Orelabrutinib Phase 3 in PPMS ongoing; SPMS Phase 3 to initiate Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":1126300000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127855,"accession_number":"0001104659-25-097663","cik":1953926,"company_name":"Zenas BioPharma, Inc.","ticker":"ZBIO","form_type":"8-K","filed_at":"2025-10-08T23:59:59+00:00","items":["1.01","2.02","8.01","3.02","7.01","9.01"],"status":"ready","headline":"Zenas licenses three autoimmune candidates from InnoCare; raises $120M in PIPE","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["License grants Zenas rights to orelabrutinib (BTK inhibitor) for MS globally and non-oncology indications outside Greater China & SE Asia.","Also obtains worldwide rights to ZB021 (oral IL-17AA/AF inhibitor) and ZB022 (brain-penetrant TYK2 inhibitor) excluding Greater China & SE Asia.","Upfront consideration: $35M cash + 5M shares (~10.6% of ZBIO outstanding); additional near-term milestones up to $65M cash + 2M shares.","Potential milestones total up to $1.4B across orelabrutinib ($723M), ZB021 ($656M), and ZB022 ($656M); royalties range high-single to high-teens.","PIPE raises ~$120M gross at $19.00 (institutional) and $20.85 (directors/officers) per share; estimated pro forma cash $302M (Sept 30, 2025) funds ops into Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1126300000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144626,"accession_number":"0001104659-25-085982","cik":1953926,"company_name":"Zenas BioPharma, Inc.","ticker":"ZBIO","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["1.01","2.01","2.03","7.01","9.01"],"status":"ready","headline":"Zenas BioPharma secures up to $300M from Royalty Pharma for obexelimab royalty","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Royalty Pharma pays $75M upfront; additional $75M upon INDIGO trial success, $75M on FDA approval for IgG4-RD, $75M on FDA approval for SLE.","Royalty Pharma receives 5.5% royalty on worldwide net sales of obexelimab and certain other payments.","Zenas expects cash to fund operations through Q1 2027; topline Phase 3 INDIGO results expected year-end 2025.","Obexelimab is in Phase 3 for IgG4-RD, Phase 2 for RMS and SLE; potential U.S. launch in H1 2027 if approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1126300000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144625,"accession_number":"0001104659-25-076464","cik":1953926,"company_name":"Zenas BioPharma, Inc.","ticker":"ZBIO","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zenas BioPharma Q2 net loss $52.2M; cash $274.9M; obexelimab trials on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $52.2M for Q2 2025, compared to $38.0M in Q2 2024.","Cash, cash equivalents and investments of $274.9M as of June 30, 2025; expected runway into Q4 2026.","Phase 3 INDIGO trial (IgG4-RD) topline results expected around year-end 2025.","Phase 2 MoonStone trial (RMS) enrollment completed; results early Q4 2025.","Phase 2 SunStone trial (SLE) enrollment expected by year-end 2025; topline mid-2026."],"consensus_eps_estimate":-1.071,"consensus_eps_actual":-2.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":10000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1126300000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163021,"accession_number":"0001104659-25-058892","cik":1953926,"company_name":"Zenas BioPharma, Inc.","ticker":"ZBIO","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Zenas BioPharma holds 2025 annual meeting; director Ting Xiao not re-elected, board reduced to 8","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Leon O. Moulder, Jr. and Hongbo Lu, Ph.D. elected as Class I directors for three-year terms.","Vote totals: Moulder 34,077,048 for; Lu 33,266,315 for; broker non-votes 1,467,979 each.","Board size reduced from 9 to 8 upon departure of Ting Xiao, who did not stand for re-election.","Ratification of Ernst & Young LLP as independent auditor for fiscal 2025 approved with 35,856,550 votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1126300000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163020,"accession_number":"0001104659-25-056215","cik":1953926,"company_name":"Zenas BioPharma, Inc.","ticker":"ZBIO","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zenas BioPharma updates pipeline timelines; obexelimab Phase 3 IgG4-RD data due year-end 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 INDIGO trial (IgG4-RD) topline results expected year-end 2025; over 190 patients enrolled.","Phase 2 MoonStone (RMS) primary endpoint (12-week new T1 Gd+ lesions) data expected early Q4 2025.","Phase 2 SunStone (SLE) primary endpoint (24-week BICLA) data expected mid-2026.","Q1 2025 cash of ~$314M; management expects cash runway into Q4 2026.","Prior Phase 2 IgG4-RD showed 93% ongoing response; SLE optimized exposure effect size 35% vs placebo."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1126300000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163019,"accession_number":"0001104659-25-048948","cik":1953926,"company_name":"Zenas BioPharma, Inc.","ticker":"ZBIO","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zenas BioPharma Q1 net loss $33.6M; cash $314.2M; pipeline milestones set","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $314.2M as of March 31, 2025; runway expected into Q4 2026.","Net loss $33.6M in Q1 2025 vs. $27.8M in Q1 2024; R&D spend $34.9M (+$12.3M YoY).","License revenue of $10.0M from Zai Lab sublicense for thyroid eye disease program.","Phase 3 INDIGO (IgG4-RD) topline results expected around year-end 2025.","Phase 2 MoonStone (RMS) topline early Q4 2025; Phase 2 SunStone (SLE) topline mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":10000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1126300000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180938,"accession_number":"0001104659-25-009368","cik":1953926,"company_name":"Zenas BioPharma, Inc.","ticker":"ZBIO","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zenas BioPharma reports preliminary $350M cash; key obexelimab trial readouts in 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary unaudited cash, equivalents, and short-term investments ~$350M as of Dec 31, 2024; expected to fund ops into Q4 2026.","Phase 3 INDIGO trial (IgG4-RD) enrollment complete; topline results expected year-end 2025.","Phase 2 MoonStone (RMS) 12-week primary endpoint results expected Q3 2025; Phase 2 SunStone (SLE) enrollment to finish in 2025.","Out-licensed thyroid eye disease programs (ZB001) to Zai Lab for Greater China; received upfront fee plus milestones and royalties.","Raised ~$458.7M in aggregate gross proceeds from Series C and IPO to fund obexelimab development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1126300000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197810,"accession_number":"0001104659-24-124616","cik":1953926,"company_name":"Zenas BioPharma, Inc.","ticker":"ZBIO","form_type":"8-K","filed_at":"2024-12-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zenas provides obexelimab trial updates: Ph3 INDIGO topline end-2025, Ph2 data 2025-2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 INDIGO trial in IgG4-RD fully enrolled (over 190 patients); topline results expected year-end 2025.","Phase 2 MoonStone trial in RMS enrolling; 12-week primary endpoint data expected Q3:2025.","Phase 2 SunStone trial in SLE enrolling; 24-week primary endpoint data expected 1H:2026.","Preliminary interim data from Cohort 1 of Phase 2 SApHiAre trial in wAIHA provided.","Company states capitalized for clinical data readouts into Q4:2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1126300000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197809,"accession_number":"0001104659-24-116346","cik":1953926,"company_name":"Zenas BioPharma, Inc.","ticker":"ZBIO","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zenas Q3 2024: Net loss $38.6M; raised $258.7M IPO; obexelimab INDIGO topline by end 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Completed IPO raising $258.7M gross proceeds; cash $386.8M to fund into Q4 2026.","Phase 3 INDIGO (IgG4-RD) completed enrollment; topline results expected by end 2025.","Initiated Phase 2 MoonStone (RMS) and SunStone (SLE); MoonStone results Q3 2025, SunStone topline H1 2026.","Net loss $38.6M vs net income $35.6M (prior year had BMS collaboration); R&D $33.5M vs $9.4M.","Appointed CCO Orlando Oliveira and CLO Jeff Held; out-licensed ZB005 for upfront and milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":-28.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1126300000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214006,"accession_number":"0001104659-24-100177","cik":1953926,"company_name":"Zenas BioPharma, Inc.","ticker":"ZBIO","form_type":"8-K","filed_at":"2024-09-16T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Zenas BioPharma completes IPO; adopts restated charter and amended bylaws","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Authorized 175M shares of common stock and 25M shares of undesignated preferred stock.","Eliminated stockholder ability to act by written consent and removed prior preferred series references.","Amended bylaws establish procedures for stockholder proposals and director nominations.","Charter and bylaws became effective upon IPO consummation on September 16, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1126300000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}